

1614
IFW
PATENT / DOCKET NO.: 6643R5
CUSTOMER NO.: 27683

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Joseph K. Agyin, et al.

Serial No.: 09/676,032

Filed: September 29, 2000

For: Compounds and Methods for Use
Thereof In the Treatment of Cancer
or Viral Infections

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is a Fourth Supplemental Information
Disclosure Statement, PTO-1449 Form and copies of cited
references.

[X] No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)	<u>SMALL ENTITY</u>			<u>OTHER THAN A SMALL ENTITY</u>	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT FEE.	<u>OR</u>	RATE	ADDIT. FEE
TOTAL		minus	=	0	x 9	\$	OR	x 18	\$0
INDEP		minus	=	0	x 42	\$	OR	x 84	\$0
[]	FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				+ 140	\$	OR	+ 280	\$0
					TOTAL	\$	OR	TOTAL	\$0

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

[] Please charge Haynes and Boone, LLP Deposit Account No. 08-1394 in the amount of \$_____.

[] A check in the amount of \$_____ is attached.

[] The Commissioner is hereby petitioned under 37 CFR §1.136(a) to grant any extension of time needed for timely response to the Office Action dated in the above-identified application to preserve pendency of said application.

[X] The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment to Haynes and Boone, LLP Deposit Account No. 08-1394.

[] Any additional filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims.

[X] Any patent application processing fees under 37 C.F.R. § 1.17.


Respectfully submitted,

Gloria L. Norberg

Gloria L. Norberg

Registration. No. 36,706

Date: May 7, 2004
HAYNES AND BOONE, LLP
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 512-867-8528
Facsimile: 210-200-0853



PATENT / DOCKET NO.: 6643R5
CUSTOMER NO.: 027683

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Joseph K. Agyin, et al.

Serial No. 09/676,032

Filed: September 29, 2000

For: Compounds and Methods for Use
Thereof in the Treatment of Cancer
or Viral Infections

§
§
§
§
§
§
§
§
§

Group Art Unit: 1614

Examiner: Delacroix Muirheid, C.

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 CFR §1.56, and in accordance with the practice under 37 CFR §1.97 and §1.98, the Examiner's attention is directed to the documents listed on the enclosed modified Form PTO-1449. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists. A copy of the listed information is attached.

It is hereby certified that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of the present Supplemental Information Disclosure Statement.

No fees are believed due for the filing of the present Supplemental Information Disclosure Statement, however, should any fees be deemed necessary, the Commissioner is hereby authorized to charge any fees which may be required to Deposit Account 08-1394.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Respectfully submitted,

Gloria L. Norberg

Gloria L. Norberg
Agent for Applicant
Registration No.: 36,706


Date: May 7, 2004
HAYNES AND BOONE, LLP
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 512-867-8528
Facsimile: 210-200-0853

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in a box addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

May 10, 2004
DATE

Julie Schwartz
TYPE OR PRINT NAME

Julie Schwartz
SIGNATURE



In Place of Form		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/676,032
				Filing Date	September 29, 2000
				Applicant(s)	Joseph K. Agyin, et al.
				Art Unit	1614
				Examiner Name	Delacroix Muirheid, C.
SHEET	1	OF	1	Attorney Docket Number	6643R5

U. S. PATENT DOCUMENTS				
Examiner's Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		3,574,845	04-13-1971	Actor, et al.

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document (Country Code - Number - Kind)	Publication Date MM-DD-YYYY	Patentee or Applicant of Cited Document	Translation Y/N
		JP H06-505733	06-30-1994	Gazzard (PCT equivalent WO 92/16208)	Yes, PCT equivalent
		JP S42-23274-A	unclear (priority date 05-23-1963)	Wagner, et al. (US equivalent 3,370,957)	Yes, US equivalent

OTHER PRIOR ART		
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item; date, page(s), volume- issue number(s), publisher, city/country where published
		DELATOUR, et al., "Oncology- Embryotoxic and Antimitotic Properties of Parbendazole, Mebendazole, and Cambendazole", C.R. Acad. Sc. Paris, Series D, (1976), pp. 517-518, Vol. 282, No. 5. (English translation thereof)
		LAPRAS, et al. "Antimitotic Properties of Some Embryotoxic and Teratogenic Anthelmintics Derived from Benzimidazole", Proceeding of the European Society of Toxicology, (1977), pp. 294-296. (English translation thereof)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.